Novo Nordisk's CFO expects US growth boost this year

In spite of price pressure in the insulin business and increased US competition Novo Nordisk's CFO expects the company to grow its US business in 2021.
Novo Nordisk CFO Karsten Munk Knudsen | Photo: Novo Nordisk / PR
Novo Nordisk CFO Karsten Munk Knudsen | Photo: Novo Nordisk / PR
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

Novo Nordisk expects to turn its US growth up a notch, since the company is back to growing on this market after a stagnation and price pressure-riddled 2019.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading